帕利哌酮与利培酮在治疗首发儿童青少年精神分裂症的临床对照

目的 观察帕利哌酮缓释片与利培酮片治疗首发儿童青少年精神分裂症的效果及安全性.方法 将66例首发儿童青少年精神分裂症患者随机分成A组 (帕利哌酮组) 和B组 (利培酮组) , 每组患者各33例.A组患者给予帕利哌酮缓释片口服治疗;B组患者给予利培酮片口服治疗.2组患者治疗时间均为8周.在治疗前、治疗第1、2、4、8周末, 用PANSS评定2组患者的临床疗效, 用TESS评定患者的不良反应.结果 对比治疗前, 2组患者的PANSS量表总分及各因子分值均为下降明显 (P<0.05或P<0.01) .治疗第1周末, A组患者的PANSS总分低于B组, 差异有统计学意义 (P<0.05) , 其余各因子无明显差异 (P>0.05) .不良反应方面, A组的发生率明显低于B组 (P<0.01) .结论 对于首发儿童青少年精神分裂症的治疗, 帕利哌酮缓释片起效速度较利培酮片更快, 同时不良反应较少, 安全性更高.

Comparative Study of Paliperidone ER Tablets and Risperidone Tablets in Treatment of Childhood and Adolescents First Episode Schizophrenia

Objective To explore the efficacy and safety of Paliperidone extended-release tablets (Paliperidone ER) and Risperidone tablets in treatment of childhood and adolescents first episode schizophrenia.Methods 66 children with first-episode schizophrenia were randomly divided into Paliperidone group (n=33, treated with Paliperidone ER) and Risperidone group (n=33, orally took Risperidone tablets) and treated for 8 weeks.The efficacy and adverse reactions were assessed with positive and negative syndrome scale (PANSS) and treatment emergent symptom scale (TESS) before and 1, 2, 4, 8 weeks after the treatment.Results The total score and the factor scores of PANSS in the two groups were significantly decreased after the treatment (P<0.05 or P<0.01) .At the first weekend, the score of PANSS was significantly lower in Paliperidone group than that in the Risperidone group (P<0.05) .The other factors had no significant differences (P>0.05) .In comparison of the adverse reactions between the two groups, the adverse drug reaction incidence of Paliperidone group was lower than that of Risperidone group (P <0.01) .Conclusions Paliperidone ER in the treatment of childhood and adolescents first episode schizophrenia has a rapid effect, less adverse reactions, and a high safety.